•
Sep 30, 2021

iRhythm Q3 2021 Earnings Report

Reported financial results with revenue increase driven by volume growth, offset by Medicare reimbursement rate decrease.

Key Takeaways

iRhythm Technologies reported a revenue of $85.4 million for Q3 2021, an 18.7% increase compared to Q3 2020. The increase was driven by volume growth but was partially offset by a decrease in Zio XT Medicare reimbursement rates. Gross margin was 65.7%, down from 74.7% in the same period last year. The net loss for the quarter was $23.7 million, or $0.81 per share.

Revenue increased by 18.7% to $85.4 million compared to Q3 2020.

Gross margin decreased to 65.7% from 74.7% in the same period last year.

Adjusted EBITDA was negative $8.7 million.

Cash and Short-Term Investments were $256.8 million as of September 30, 2021.

Total Revenue
$85.4M
Previous year: $71.9M
+18.7%
EPS
-$0.81
Previous year: -$0.17
+376.5%
Gross Margin
65.7%
Previous year: 74.7%
-12.0%
Gross Profit
$56.1M
Previous year: $53.7M
+4.5%
Cash and Equivalents
$167M
Previous year: $95.3M
+75.6%

iRhythm

iRhythm

iRhythm Revenue by Segment

Forward Guidance

iRhythm expects revenue to range from $317 million to $319 million for the full year 2021, representing year over year growth of approximately 20%.

Challenges Ahead

  • Unforeseen ongoing impacts from the COVID-19 Delta variant.
  • Customer staffing challenges.
  • Delayed new account launches and expansion.